WO2019054960A3 - Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging) - Google Patents

Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging) Download PDF

Info

Publication number
WO2019054960A3
WO2019054960A3 PCT/TR2017/050593 TR2017050593W WO2019054960A3 WO 2019054960 A3 WO2019054960 A3 WO 2019054960A3 TR 2017050593 W TR2017050593 W TR 2017050593W WO 2019054960 A3 WO2019054960 A3 WO 2019054960A3
Authority
WO
WIPO (PCT)
Prior art keywords
injection
aging
delaying
preventing
telomerase activity
Prior art date
Application number
PCT/TR2017/050593
Other languages
French (fr)
Other versions
WO2019054960A2 (en
Inventor
Iskender Alkin SOLMAZ
Isilay KAVADARLI
Murat Kubilay TURKMEN
Original Assignee
Solmaz Iskender Alkin
Kavadarli Isilay
Turkmen Murat Kubilay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solmaz Iskender Alkin, Kavadarli Isilay, Turkmen Murat Kubilay filed Critical Solmaz Iskender Alkin
Publication of WO2019054960A2 publication Critical patent/WO2019054960A2/en
Publication of WO2019054960A3 publication Critical patent/WO2019054960A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The method subject to the invention includes administering natural or synthetic (obtained in laboratory) active ingredients that will activate telomerase enzyme described herein so that the active ingredients will have rapid and high bioavailability on the targeted tissue. Thanks to administration of the active ingredient activating telomerase enzyme activity subject to the invention in drop form, pomade form, gel form, sub-tenon injection, subconjunctival injection, subconjunctival extended release (short or long term), anterior chamber injection, posterior chamber (intravitreal) injection, intravitreal extended release (short or long term), peribulbar or retrobulbar injection form into the eye; impacts of aging on tear film, conjunctiva, sclera, cornea, trabecular meshwork, iris, pupil, lens, blood vessels feeding the eye, choroid, ciliary body, retina and optic nerves can be delayed, stopped or improved.
PCT/TR2017/050593 2016-11-28 2017-11-23 Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging) WO2019054960A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2016/17350A TR201617350A2 (en) 2016-11-28 2016-11-28 Increasing Ophthalmic Telomerase Activity With Topical And Local Ocular Applications And Preventing, Slowing Down, Stopping And / Or Improving Defects Or Diseases Due To Degenerative Processes (Aging Etc.)
TR2016/17350 2016-11-28

Publications (2)

Publication Number Publication Date
WO2019054960A2 WO2019054960A2 (en) 2019-03-21
WO2019054960A3 true WO2019054960A3 (en) 2019-05-23

Family

ID=65723822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050593 WO2019054960A2 (en) 2016-11-28 2017-11-23 Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging)

Country Status (2)

Country Link
TR (1) TR201617350A2 (en)
WO (1) WO2019054960A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173371A1 (en) * 2016-04-01 2017-10-05 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
CA3145888A1 (en) * 2018-07-31 2020-02-06 Isilay KAVADARLI Ophthalmic formulations and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BABIZHAYEV, M.A. ET AL.: "Telomere attrition in lens epithelial cells -a target for N-acetylcarnosine therapy", FRONTIERS IN BIOSCIENCE, vol. 15, 1 June 2010 (2010-06-01), pages 934 - 956, XP055611760 *
DOW, C.T. ET AL.: "Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study.", CLINICAL OPHTHALMOLOGY, vol. 10, 28 January 2016 (2016-01-28), pages 243 - 249, XP055611762 *

Also Published As

Publication number Publication date
WO2019054960A2 (en) 2019-03-21
TR201617350A2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
Kels et al. Human ocular anatomy
WO2008111497A1 (en) Prophylactic or therapeutic agent for ophthalmic disease associated with oxidative stress, comprising triterpenoid as active ingredient
JP2015509500A5 (en)
Taneri et al. Surface ablation techniques
JP2015134824A5 (en)
RU2009145939A (en) PREVENTIVE OR THERAPEUTIC APPLICATION USED IN DISEASES OF THE REAR EYE
RU2015144119A (en) ACCELERATED HEALING OF EYE DAMAGE WITH ANGIOTENZINE PEPTIDES
WO2019054960A3 (en) Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging)
MX2023009352A (en) Methods for ophthalmic delivery of roflumilast.
TN2016000259A1 (en) Salbutamol (albuterol) eye protective medicament.
Zheng et al. Angle-closure glaucoma following periorbital botulinum toxin injection.
Liu et al. Tissue responses and wound healing following laser scleral microporation for presbyopia therapy
RU2508134C1 (en) Method of treating choroidal melanoma with size of more than 6,5 mm
Park et al. Spontaneous malignant glaucoma in a longstanding hypotonous eye
Leung et al. Retinal tear and raised intraocular pressure following unintentional intraocular botulinum toxin type A injection
Bastion Pneumatic retinopexy for treatment of posterior pole detachment following vitreoretinal surgery for diabetic tractional retinal detachment threatening the fovea
Kazakbaeva MyoRing Implantation in Comparison with MyoRing Implantation Combined with Corneal Collagen Crosslinking for Keratoconus
Arora et al. Ophthalmic Drug Delivery System-A Concise Review on its Conventional and Novel Approaches
Bodenlle et al. “Sclero-DALK”: New approach for treatment of superficial corneal leukoma
Kim et al. Neodymium YAG laser and surgical synechiolysis of iridocapsular adhesions
Takkar et al. Re: Bouheraoua et al.: Decreased Corneal Sensation and Subbasal Nerve Density, and Thinned Corneal Epithelium as a Result of 360‐Degree Laser Retinopexy
Idrus Penatalaksanaan Keratokonus Progresif menggunakan Corneal Cross-linking: Tinjauan Kepustakaan
Verma et al. An insight into ocular drug delivery system
Bhandari et al. Shylaja (2015) Necrotising Scleritis Post Trans-Scleral Diode Cyclophotocoagulation-A Novel Approach
Sood Various toxicities: case report

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17924957

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 12/07/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17924957

Country of ref document: EP

Kind code of ref document: A2